Veru Inc. Employee Directory
Biotechnology ResearchFlorida, United States51-200 Employees
Veru Inc. is a late-stage biopharmaceutical company focused on developing medicines for cardiometabolic and inflammatory diseases. Its late-stage portfolio centers on two novel small molecules: enobosarm, a selective androgen receptor modulator intended to enhance weight loss by targeting fat reduction while preserving lean mass, and sabizabulin, a microtubule disruptor aimed at reducing inflammation in atherosclerotic cardiovascular disease. Enobosarm is being developed to complement GLP-1 receptor–based weight-loss therapies by improving tissue selectivity and overall body composition. The company targets patients with cardiometabolic and inflammatory conditions and seeks to address weight management and inflammatory processes that underlie cardiovascular disease. Veru is based in Miami, Florida, and operates in the biotechnology research sector with a focus on novel therapeutics. In 2025, the firm participated in the Jones Healthcare and Technology Innovation Conference to engage with stakeholders on its clinical programs.